Singapore, Feb. 18 -- US-basedBostonGene, the developer of the leading AI foundation model for tumour and immune biology, has announced a strategic collaboration with Japanese pharmaceutical firmDaiichi Sankyo.

The collaboration will integrate AI-driven translational intelligence into the core of an antibody drug conjugate (ADC) development programme of Daiichi Sankyo to move beyond standard exploratory biomarker analysis and deliver decision-ready insights that directly inform patient selection strategies, development prioritisation and translational positioning.

By generating digital twin representations from hundreds of thousands of multiomic and histopathologic patient profiles, BostonGene identifies the precise biological signature...